https://www.selleckchem.com/pr....oducts/solutol-hs-15
disease progression warrants larger studies to further investigate potential clinical utility.Objectives During crizotinib clinical evaluation, visual disturbances, generally of grade 1 severity, were frequently reported adverse events (AE). Consequently, ophthalmologic assessments were included in a patient subgroup enrolled in PROFILE 1001 (NCT00585195), a phase 1, open-label, single-arm trial of crizotinib in patients with advanced non-small-cell lung cancer and are reported here. Materials and methods At least 30 patients were
Like
Comment
Share
